A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants

• Status: Not yet recruiting
• Trial end date: 2026-10-08
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Carboplatin; Ipilimumab; Nivolumab; Pemetrexed

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com

Inclusion Criteria:

• Histologically proven diagnosis of Malignant Pleural Mesothelioma (MPM) with determination of epithelioid vs non-epithelioid histology

• Must have advanced unresectable disease that is not amenable to therapy with curative intent (surgery with or without chemotherapy)

• Available tumor samples for centralized testing

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1

• Measurable disease

Exclusion Criteria:

• Primitive peritoneal, pericardial, testis or tunica vaginalis mesothelioma

• Brain metastasis, except if surgically resected or treated with stereotaxic radiotherapy

• Prior therapy for MPM (including chemotherapy, radical pleuropneumonectomy and non-palliative radiotherapy)

Other protocol-defined inclusion/exclusion criteria apply